Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a global life sciences and diagnostics innovator whose news flow is closely followed by investors, healthcare professionals and industry observers. The company regularly issues press releases on its financial performance, capital allocation decisions and participation in major healthcare conferences, providing insight into how its life sciences and diagnostics businesses are performing and evolving.
On this page, readers can find news about Danaher’s quarterly and annual results, including updates on revenue trends, non‑GAAP core revenue growth and adjusted earnings, as described in its earnings releases and related Form 8‑K filings. The company frequently hosts earnings conference calls and webcasts, and it posts accompanying slide presentations, non‑GAAP reconciliations and notes on historical and anticipated financial performance in its investors materials.
Danaher also announces regular quarterly cash dividends on its common stock and discloses share repurchase authorizations, giving shareholders visibility into its capital allocation approach. In addition, news items cover leadership and governance developments, such as planned transitions in senior executive roles and changes in board composition, as documented in the company’s communications and SEC reports.
Beyond financial and corporate updates, Danaher’s news includes product and research announcements from its operating companies. For example, Beckman Coulter Diagnostics, a Danaher company, has reported the launch of a fully automated Brain‑derived Tau research use only immunoassay test and the development of an Aβ‑42 research use only immunoassay test to support neurodegenerative disease research. These stories illustrate how Danaher’s diagnostics businesses contribute to advanced clinical and research capabilities.
By reviewing the DHR news feed, users can monitor earnings announcements, dividend declarations, conference presentations, governance updates and scientific developments across Danaher’s life sciences and diagnostics platform. This page can be a useful resource for tracking how the company communicates its strategy, performance and innovation activities over time.
Cytiva has acquired Vanrx Pharmasystems, a Canadian firm specializing in robotic aseptic filling machines, marking its first acquisition since becoming an operating company of Danaher in April 2020. This acquisition aligns with global trends towards smaller batch manufacturing and personalized therapies in the growing USD 300 billion biologics market. The addition enhances Cytiva's solutions from drug development to drug product, facilitating faster delivery of therapies to patients. Vanrx's expertise in aseptic filling complements Cytiva's existing manufacturing capabilities.
Danaher Corporation (NYSE: DHR) reported strong financial results for Q4 and full year 2020. Q4 net earnings reached $1.2 billion ($1.66 per share), up 55% year-over-year, while revenues climbed 39% to $6.8 billion. Full year net earnings totaled $3.6 billion ($4.89 per share), reflecting a 50% increase, with total revenues at $22.3 billion, a 24.5% rise. The company anticipates mid to high-teens non-GAAP core revenue growth for Q1 2021 and low-double digits for the full year. The acquisition of Cytiva significantly bolstered Danaher's market position and long-term value.
Beckman Coulter announced the launch of the DxH 560 AL, a compact tabletop analyzer designed for small to mid-sized laboratories. This innovative device features Auto-Loading functionality, allowing for continuous sample addition of up to 50, while minimizing manual tasks and resource usage. It requires only 17 μL of blood, making it ideal for difficult-to-draw patients, and delivers results in under 60 seconds. The DxH 560 AL aims to provide large laboratory efficiency at a lower cost, enhancing productivity without exceeding budgetary constraints.
Beckman Coulter announced the launch of the DxH 560 AL, a tabletop analyzer designed for small to mid-sized laboratories. This innovative device features auto-loading functionality, accommodating up to 50 samples and requiring only a 17 μL sample volume, among the lowest in the market. The DxH 560 AL provides results in under 60 seconds, enhancing efficiency. It also includes advanced security features for patient data protection. The analyzer is part of the DxH 500 series, offering high-throughput capabilities while remaining budget-friendly.
On January 13, 2021, Danaher Corporation (NYSE: DHR) announced strong financial performance for Q4 2020 during the J.P. Morgan Healthcare Conference. The company expects core revenue growth, including Cytiva, to exceed previous guidance, driven by robust results in Life Sciences and Diagnostics segments. Estimated revenues rose approximately 38.5% year-over-year, with non-GAAP core revenue growth estimated at 15%. Danaher will report full earnings on January 28, 2021.
Danaher Corporation (NYSE: DHR) will have its President and CEO, Rainer M. Blair, present at the J.P. Morgan Healthcare Conference on January 13, 2021, at 10:50 a.m. ET. This presentation will be available via a live audio webcast and will be archived for later access on Danaher’s website.
As a leader in science and technology, Danaher focuses on solving complex challenges across healthcare and environmental markets, employing over 67,000 associates committed to improving quality of life globally.
Danaher Corporation (NYSE: DHR) has announced its upcoming quarterly earnings conference call for the fourth quarter of 2020, scheduled for January 28, 2021, at 8:00 a.m. ET. The call will last approximately one hour and will be available via webcast on Danaher's website. A replay will be accessible after the call until February 11, 2021. Additional related materials will be posted on the website at 6:00 a.m. ET on the call date.
Danaher Corporation (NYSE: DHR) announced the appointment of Dr. Jose-Carlos Gutierrez-Ramos as Senior Vice President and Chief Scientific Officer. Reporting directly to President and CEO Rainer M. Blair, Gutierrez-Ramos will lead Danaher’s science and technology strategy. A seasoned expert, he joins from Abbvie, where he was Head of Global Drug Discovery. His previous roles include leadership positions at Repertoire Immune Medicines and Pfizer, among others. Gutierrez-Ramos holds a Ph.D. in Immunology and extensive experience in academia and R&D.
Danaher Corporation (NYSE: DHR) appointed Jennifer L. Honeycutt as Executive Vice President, effective January 1, 2021. Honeycutt will oversee Beckman Coulter Life Sciences, Integrated DNA Technologies, and other key businesses. Previously, she served as Vice President and Group Executive for Pall and IDT in China, and President of Pall and Beckman Coulter. Her leadership is noted for driving growth within the Life Sciences platform. With 20 years at Danaher, she holds degrees in Chemistry and French, along with an MBA in Technology Management.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.18 per share for common stock, scheduled for payment on January 29, 2021 to shareholders of record as of December 28, 2020. Additionally, a dividend of $11.875 per share will be paid for its 4.75% Series A Mandatory Convertible Preferred Stock and $12.50 for the 5.00% Series B Mandatory Convertible Preferred Stock, both payable on January 15, 2021 to holders of record on December 31, 2020.